Best Pulmonology Companies in England, United Kingdom
The 55 best Pulmonology companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Apollo Therapeutics.
Ranked: Best Pulmonology companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Apollo Therapeutics Developer of therapeutic programs based on biological and medical research | $372M | 34 mo ago | 11 | Richard Mason CEO | Series C | — | — |
| 2 | Pulmocide Developer of inhaled antifungal medicines for treating respiratory lung infections | $205M | 43 mo ago | 9 | Pete Strong Co-Founder | Series C | 124 patents Polymorph forms and manufacturing processes for triazole antifungal agents | — |
| 3 | Redx Pharma Developer of small molecule medicines for fibrotic disease and oncology | $163M | 33 mo ago | 89 | Lisa Anson CEO | Acquired | 423 patents Patents concentrated in chemistry & materials | — |
| 4 | Circassia Pharmaceuticals Products to treat asthma, Chronic Obstructive Pulmonary Disease (COPD) and various allergies. | $157M | 73 mo ago | 128 128 → 135 (+5%) | Charles Swingland Co-Founder | Public | — | 1 launch |
| 5 | Owlstone Medical Developer of non-invasive breath-based diagnostics for cancer and infectious diseases 67Funding top 18%Moat top 28%Product top 36%Talent top 38% All 9 signals ▾Fundingtop 18% Moattop 28% Producttop 36% Talenttop 38% Growthtop 40% Markettop 44% Techtop 44% Globalbottom 45% Newsbottom 18% Funding: Raised $150M across 16 rounds · 16 rounds over 15 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 67/100 | $150M | 9 mo ago | 199 199 → 147 (-26%) | David Alonso Co-Founder & COO | Series E | — | 1 job opening |
| 6 | Synairgen Developer of pharmaceutical products focused on severe respiratory conditions | $124M | 69 mo ago | 24 24 → 21 (-12%) | — | Public | 4 patents Therapeutic use of interferon‑beta/lambda for treating rhinovirus infections in elderly patients. | — |
| 7 | ReViral Developer of antiviral compounds for RSV | $121M | 70 mo ago | 28 | Khattereh Ahmadi Co-Founder | Acqui-Hired | 91 patents Antiviral benzodiazepine derivatives for treating respiratory syncytial virus infections | — |
| 8 | Oxagen Developer of drugs for inflammatory and respiratory diseases | $86M | 199 mo ago | 3 | Richard Edwards Managing Director | Deadpooled | 153 patents CRTH2 antagonist small‑molecule pharmaceuticals and related solid‑form formulations | — |
| 9 | Enterprise Therapeutics Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis | $86M | 29 mo ago | 9 | Martin Gosling Co-Founder | Acquired | 70 patents Small-molecule ENaC inhibitors for treating hypertension and fluid retention | — |
| 10 | Sitryx Biotechnology company focused on immunometabolism, developing therapies | $69M | 36 mo ago | 17 | Paul-Peter Tak Co-Founder & Director | Series B | — | — |
| 11 | Senzer Developer of respiratory devices for the delivery of pharmaceutical cannabinoids | $65M | 86 mo ago | 9 | Alex Hearn Founder | Funding Raised | 15 patents Cannabinoid inhalation devices, cartridges, and aerosol formulations for medical delivery | — |
| 12 | Verona Pharma Developer of drugs for the treatment of respiratory diseases such as asthma, COPD | $56M | 72 mo ago | 27 | — | Acquired | 329 patents Patents concentrated in health & consumer products | — |
| 13 | Funxional Therapeutics Developer of anti-inflammatory therapies for respiratory disorders | $27M | 194 mo ago | 1 | Konstantinos Efthymiopoulos CEO | Series B | — | — |
| 14 | Prosonix Develops inhaled respiratory medicines. | $27M | 169 mo ago | 32 | — | Acquired | 103 patents Manufacturing multi-component crystalline particles for inhalable pharmaceutical therapies. | — |
| 15 | Anaxsys Continuous real-time Respiratory rate counter | $9M | 127 mo ago | 2 | — | Deadpooled | 42 patents Advanced gas and vapor sensing, electrochemical sensor tuning, medical respiratory diagnostics. | — |
| 16 | DJS Antibodies Developer of antibody therapeutics for inflammatory conditions | $8M | 29 mo ago | 16 | Robert Michael CEO | Acquired | 12 patents Therapeutic antibody polypeptide design and production technologies | — |
| 17 | Ario Pharma Develops drugs for the treatment of respiratory diseases | $3M | 151 mo ago | 1 | John Ford Co-Founder & CEO | Deadpooled | — | — |
| 18 | Exvastat Developer of repurposed drug for acute respiratory distress syndrome | $3M | 45 mo ago | 8 | David Cavalla CEO | Seed | 2 patents Tyrosine‑kinase inhibitor formulations and repurposing for acute respiratory distress therapy | — |
| 19 | Albus Health Developer of real-time respiratory monitoring system | $2M | 30 mo ago | 7 | Mikesh Udani CEO | Seed | — | 1 expansion |
| 20 | Nuformix Developer of drugs for the treatment of fibrosis and oncology | $2M | 39 mo ago | 4 | Stephen Cash Co-Founder | Public | 48 patents Pharmaceutical cocrystal and salt forms of active drug molecules | — |
| 21 | Bioxydyn Provider of quantitative imaging biomarker services for pharmaceutical and clinical research | $2M | 165 mo ago | 8 | Geoff Parker Founder & CEO | Series A | 11 patents Pulmonary function measurement and oxygen‑enhanced medical imaging processing technologies. | 1 partnership |
| 22 | PulmoBioMed Developer of non-invasive deep lung fluid collection technology. | $2M | 25 mo ago | 5 | Sterghios Moschos Founder | Seed | 2 patents Exhaled breath sampling mouthpiece for medical diagnostic devices | — |
| 23 | BPR Medical Medical Gas Therapy Devices | $822K | 202 mo ago | 61 | — | Early Stage | 55 patents Safety monitoring and control devices for medical gas delivery systems | 1 job opening |
| 24 | Mursla Provider of diagnostic device for cancer detection | $547K | 70 mo ago | 9 | Victor Serdio Co-Founder | Seed | 32 patents Isolation, characterization, and biosensor conditioning of tissue-specific extracellular vesicles. | — |
| 25 | ChestPal AI-powered digital stethoscope to assist frontline healthcare providers | $519K | 37 mo ago | 4 | Helena Binetskaya Co-Founder & CEO | Seed | 6 patents Acoustic analysis of respiratory sounds for digital health monitoring and diagnosis | — |
| 26 | Inspira Pharmaceuticals Developer of therapeutics for respiratory diseases | $518K | 62 mo ago | 5 | Nick Woolf Co-Founder | Seed | — | — |
| 27 | Quvium Early warning solution for asthma patients | $460K | 168 mo ago | 1 | Steven Schmidt Founder & CEO | Seed | 14 patents Remote cough detection and analysis for digital health monitoring and telemedicine. | — |
| 28 | PenMed Developer of critical care devices to improve the safety and outcomes of patients in intensive care units | $250K | 26 mo ago | — | Simon Cooke Co-Founder | Seed | — | — |
| 29 | Forth Therapeutics Developer of therapeutics for fibrosis treatment | — | 16 mo ago | — | Alex Leech Co-Founder & CEO | Seed | — | — |
| 30 | Alevin Therapeutics Developer of targeted integrin therapies for multiple diseases | — | 47 mo ago | 4 | Chris Moody Founder | Seed | — | — |
| 31 | Respivert Small molecule drugs for patients with Chronic Obstructive Pulmonary Disease, Cystic Fibrosis and severe… | — | 229 mo ago | 1 | William Garth Rapeport Founder | Acquired | 572 patents Indolinone-based small‑molecule kinase inhibitors for treating fibrosis and inflammatory diseases | — |
Top 12 Pulmonology companies in England
#1
Series E · Cambridge, England · founded 2004 · 199 employees$150Mraised▾
Developer of non-invasive breath-based diagnostics for cancer and infectious diseases. It offers Breath Biopsy platform for early detection and precision medicine which uses proprietary technology as a microchip that uses Field Asymmetric Ion Mobility Spectrometry (FAIMS) coupled with software to detect desired biomarkers in a patient's exhaled breath. The first application is an early screening of lung and colon cancer.
- Oct 2025Grant (prize money)$49.1M
- Mar 2025Series E$2.3M
- Jan 2025Series E$27M
- Apr 2024Series D$5M
#2
Series C · Cambridge, England · founded 2020 · 11 employees$371.5Mraised▾
Developer of therapeutic programs based on biological and medical research. The company's product pipeline include APL-9796: A first-in-class anti-ZIP12 monoclonal antibody for pulmonary hypertension, APL-045 and APL-10456, targeting neoplasms, immune disorders, and metabolic conditions via small molecules and antibodies.
- Sep 2023Series C$226.5M
- Jun 2021Series C$145M
#3
Acquired · Liverpool, England · founded 2010 · 89 employees$163.5Mraised▾
Developer of small molecule medicines for fibrotic disease and oncology. The company focuses on novel compounds against biologically or clinically validated targets. It has an extensive programme of pre-clinical research focused on Discoidin Domain Receptors. The company’s core strengths are in medicinal chemistry, translational science, and clinical development.
- Oct 2023Post IPO$17.2M
- May 2022Post IPO$42.6M
- Dec 2020Post IPO$34.1M
- Apr 2020Post IPO—
#4
Acquired · Brighton, England · founded 2014 · 9 employees$86.2Mraised▾
Enterprise Therapeutics is a developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis. Also planning to develop therapeutics for the treatment of chronic obstructive pulmonary disease (COPD) and severe asthma.
- Jan 2024Series B$33M
- Oct 2019Grant (prize money)$7.2M
- Apr 2018Series B$41.1M
- Apr 2017Grant (prize money)—
#5
Series C · London, England · founded 2013 · 9 employees$205.4Mraised▾
Developer of inhaled antifungal medicines for treating respiratory lung infections. These investigational therapies target fungal pathogens directly within the lungs to minimize systemic exposure. The drug design focuses on maintaining high concentrations at the site of infection to address conditions associated with pulmonary aspergillosis. This approach aims to provide treatment options for patients who do not respond to standard antifungal therapies.
- Dec 2022Series C$52M
- Dec 2021Series C$3.5M
- May 2021Series C$92M
- Mar 2017Series B$30.4M
#6
Series B · Oxford, England · founded 2018 · 17 employees$69Mraised▾
Biotechnology company focused on immunometabolism, developing therapies. The company exploits the link between immune function and metabolism to create first-in-class, disease-modifying drugs aiming for sustained remission. Their science regulates metabolic pathways in immune cells to restore balance disrupted in chronic conditions.
- Jul 2023Series B$39M
- Dec 2022Series A$3.7M
- Sep 2022Series A$11.8K
- Mar 2020Series A$9.6M
#7
Acquired · Oxford, England · founded 2014 · 16 employees$8Mraised▾
Developer of antibody therapeutics for inflammatory conditions. The company's proprietary platform, HEPTAD, enables the discovery of these antibodies, which has led to a pipeline that includes DJS-002, a novel antibody for fibrotic diseases.
- Jan 2024Series B$18.5M
- Feb 2022Series A$8.5M
- Dec 2020Series A$8M
- Oct 2016Seed$852.4K
#8
Public · Oxford, England · founded 2006 · 128 employees$156.6Mraised▾
Circassia is focused on developing devices for treatment of allergy and respiratory disease. The company has developed NIOX for asthma management and Tudorza to treat chronic obstructive pulmonary disease. The next-generation immunotherapy technology is in phase III testing for cat allergy and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia has also developed Flixotide/Flovent substitute and Seretide/Advair substitute. The Company is also developing a number of COPD of treatments, Duaklir US, Spiriva substitute, LABA/LAMA formulation and COPD therapy formulation.
- Jun 2020Post IPO$6.2M
- Apr 2011Series D$98M
- Dec 2009Series C$25M
- Jan 2008Series B$21.8M
#9
Acqui-Hired · London, England · founded 2011 · 28 employees$121Mraised▾
Developer of antiviral compounds for RSV. The company is developing its lead candidate RV521 as an antiviral therapy for Respiratory Syncytial Virus (RSV), which is an infection that often leads to asthma, COPD, and/or pneumonia.
- Aug 2020Series C$44M
- Aug 2018Series B$55M
- Jul 2018Series B$55M
- Sep 2015Series A$21M
#10
Public · Southampton, England · founded 2003 · 24 employees$124.1Mraised▾
Synairgen is a developer of pharmaceutical products focused on severe respiratory conditions. It is a drug discovery and development company focused on advancing approaches for severe respiratory conditions. The company is focused primarily on severe asthma and COPD, using its differentiating human biology BioBank platform. The company offers its services right from drug discovery to Phase II trials.
- Oct 2020Post IPO$103.8M
- Mar 2020Post IPO$16.6M
- Sep 2018Post IPO$3.8M
#11
Seed · Newcastle Upon Tyne, England · founded 2019 · 5 employees$1.8Mraised▾
{}
- 2024Grant (prize money)—
- Dec 2023Seed$2M
- Dec 2020Seed$996.3K
#12
Seed · Oxford, England · founded 2018 · 7 employees$2.3Mraised▾
Albus Health develops a real-time respiratory monitoring system. The device is a small non-contact device that monitors respiratory symptoms at home without the patients having to do or wear anything. The algorithms convert the information from remote wireless sensors in the device to clinical information using signal processing and machine learning.
- Dec 2023Seed$264.3K
- Dec 2023Seed$951.1K
- Mar 2023Seed$467.7K
- Dec 2022Seed$606.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Pulmonology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.